Trabectedin Market Share 2024: Global Trends, Key Players, Industry Analysis and Forecast to 2031
The global trabectedin market is expected to grow at a significant CAGR during the forecast period (2024-2031). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships and collaborations, mergers and acquisitions, geographical expansion, new product launches, to remain competitive in the marketplace. For instance, in November 2020, STADA Arzneimittel AG's subsidiary in the United Arab Emirates (UAE), STADA MENA DWC-LLC, announced a commercial licensing agreement for Yondelis (trabectedin) in Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Tunisia, United Arab Emirates (UAE), and Yemen. PharmaMar received a non-disclosed upfront payment as well as subsequent remunerations, including a regulatory milestone payment, under the terms of the license and commercialization agreement.
Get Free Sample link @ https://www.omrglobal.com/request-sample/trabectedin-market
PharmaMar kept exclusive production rights to trabectedin and sell it to STADA for clinical and commercial use in the 15 MENA markets on an exclusive basis. This new agreement follows PharmaMar's announcement on August 26th, 2019, regarding the agreement reached with Janssen Products LP (Janssen), under which PharmaMar regained commercialization rights to the product in more than 40 countries where Yondelis has already been approved, which were previously licensed to Janssen. Yondelis is now approved for the treatment of soft tissue sarcoma and recurrent ovarian cancer in various MENA countries. STADA was granted exclusive rights to sell and distribute the product in MENA nations as a result of licensing agreement and the official transfer of marketing authorizations.In August 2020, Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has begun commercialization of Yondelis in Canada, following the receipt of a Notice of Compliance from Health Canada approving the transfer of the commercial rights to Valeo. PharmaMar S.A., based in Madrid, Spain, manufactures Yondelis (trabectedin), a new marine-derived anticancer agent. As Yondelis is a globally recognised standard of care in the treatment of soft tissue sarcoma, the goal of the company was to raise awareness of its benefits and availability throughout Canada.
Full report of Trabectedin Market available @ https://www.omrglobal.com/industry-reports/trabectedin-market
Market Coverage
o By Product
o By Application
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Trabectedin Market Report by Segment
By Product
By Application
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/trabectedin-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.